Study guide

15.5 Reproductive & Sexual Health

CBCN Certified Breast Care Nurse Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CBCN Exam

CBCN Exam Facts, 2026 Blueprint & Study Plan

2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)

1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes

3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)

2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations

4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)

3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation

5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)

4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance

6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)

5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques

7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)

6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification

8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET

9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)

8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)

9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens

11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)

10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs

12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)

11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations

13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)

12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy

14 Chapter 13: Oncologic Emergencies (Nursing Practice)

13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism

15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)

14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use

16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)

15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health

15.5 Reproductive & Sexual Health

Key Takeaways Explain This Topic AI

Every patient of reproductive age should hear about infertility risk and be offered referral to a reproductive specialist before starting gonadotoxic chemotherapy.

Embryo and oocyte cryopreservation are standard fertility preservation methods, and letrozole-based stimulation keeps estradiol levels low during ovarian stimulation.

Hormonal contraception is not recommended for people with current breast cancer (CDC category 4); the copper IUD is the preferred reversible method.

Up to about 70% of breast cancer survivors report sexual problems, and applying 4% aqueous lidocaine to the vulvar vestibule before penetration reduced dyspareunia in a randomized trial.

The PLISSIT model guides sexual health discussions through Permission, Limited Information, Specific Suggestions, and Intensive Therapy.

Last updated: September 2026

Why Reproductive and Sexual Health Are Tested

Breast cancer treatment can end fertility, trigger abrupt menopause, and cause sexual dysfunction that persists for years. These topics are often left out of clinic visits unless nurses raise them. The CBCN exam expects you to initiate conversations, know the options, and time referrals correctly.

Treatment Effects on Fertility

Chemotherapy: alkylating agents such as cyclophosphamide cause the greatest ovarian damage. Risk of permanent amenorrhea rises with age (especially after 35 to 40), cumulative dose, and lower baseline ovarian reserve (for example, low anti-Müllerian hormone).

Endocrine therapy: does not itself destroy eggs, but 5 to 10 years of therapy delays childbearing while ovarian reserve declines with age.

HER2-directed and other therapies: require pregnancy avoidance during treatment and for a period afterward.

Chemotherapy-induced amenorrhea is not reliable contraception: ovulation can resume.

Fertility Preservation Options

Young women with early-stage breast cancer face significant gonadotoxic risks from alkylating chemotherapy, leading to permanent amenorrhea and premature ovarian insufficiency:

Immediate Pre-Treatment Referral: Every reproductive-age woman diagnosed with breast cancer must be offered an immediate referral to a reproductive endocrinology and infertility (REI) specialist prior to initiating systemic chemotherapy.

Cryopreservation: Oocyte and embryo cryopreservation represent the gold-standard fertility preservation methods. Controlled ovarian hyperstimulation protocols incorporate concurrent aromatase inhibitors (e.g., letrozole) to keep serum estradiol levels within safe physiological ranges throughout follicular stimulation.

Ovarian Function Suppression during Chemotherapy: The POEMS trial (in hormone receptor-negative disease) and the PROMISE-GIM6 trial (which enrolled mostly hormone receptor-positive patients) demonstrated that administering a gonadotropin-releasing hormone (GnRH) agonist (such as goserelin 3.6 mg subcutaneous injection) at least 1 to 2 weeks prior to chemotherapy initiation and continued monthly throughout chemotherapy significantly reduces the risk of premature ovarian insufficiency and increases subsequent pregnancy rates.

Additional Fertility Preservation Points

Refer early , ideally at diagnosis, before surgery if chemotherapy is likely.

Random-start stimulation can begin at any point in the menstrual cycle and usually takes about 2 weeks, so it rarely delays treatment meaningfully.

Ovarian tissue cryopreservation is an established option (no longer considered experimental) when there is no time for stimulation.

GnRH agonist ovarian protection during chemotherapy is an adjunct and does not replace cryopreservation for patients who want future pregnancy.

Cost and insurance coverage are major barriers; some states mandate coverage for fertility preservation when treatment may cause infertility.

Contraception After Breast Cancer

  • Method Use in breast cancer (CDC Medical Eligibility Criteria)
  • Copper IUD Category 1 (no restriction); preferred reversible method
  • Barrier methods, sterilization Acceptable

Combined hormonal methods, progestin-only pills, implants, injections, levonorgestrel IUD Current breast cancer: category 4 (unacceptable risk); past breast cancer with no evidence of disease for 5 years: category 3

Teach contraception needs clearly: tamoxifen and trastuzumab are harmful in pregnancy, and trastuzumab labeling advises contraception for 7 months after the last dose.

Pregnancy After Breast Cancer

Pregnancy after treatment does not appear to worsen breast cancer outcomes. Many clinicians advise waiting about 2 years after diagnosis, when recurrence risk is highest, but timing is individualized.

The POSITIVE trial enrolled women with early HR-positive breast cancer who paused endocrine therapy after 18 to 30 months to attempt pregnancy. The 3-year rate of breast cancer events (8.9%) was similar to an external control group (9.2%), and about three quarters became pregnant. Participants then resumed endocrine therapy to complete the planned course. Breastfeeding from the untreated breast is often possible, and some women can lactate from a breast treated with lumpectomy and radiation, although milk supply is usually reduced.

Sexual Health

Up to about 70% of survivors report sexual problems, often long-lasting. Causes include:

Physical: vaginal dryness and atrophy (worst with aromatase inhibitors and ovarian suppression), dyspareunia, reduced libido, fatigue, pain, loss of breast and nipple sensation, and lymphedema.

Psychological: body image distress, depression, anxiety, and fear of recurrence.

Relational: partner fears, role changes, and communication problems.

Medications: antidepressants and opioids can reduce desire and orgasm.

Assessment Models

PLISSIT: give P ermission to discuss sexual concerns; provide L imited I nformation (for example, that dryness is common on aromatase inhibitors); offer S pecific S uggestions (moisturizers, lubricants, positions); refer for I ntensive T herapy (sex therapy, pelvic floor therapy) when needed.

BETTER: B ring up the topic, E xplain concern for quality of life, T ell the patient about resources, T iming (it can be revisited any time), E ducate about side effects, R ecord the assessment.

Use inclusive language that does not assume a partner's gender or type of sexual activity.

Interventions

Vaginal moisturizers used regularly (typically 2 to 5 times weekly) and lubricants (water- or silicone-based) during sexual activity.

Topical 4% aqueous lidocaine applied to the vulvar vestibule for about 3 minutes before penetration reduced pain in a randomized trial in breast cancer survivors with dyspareunia.

Vaginal dilators and pelvic floor physical therapy for pain and muscle tension.

Low-dose vaginal estrogen or vaginal DHEA (prasterone) may be considered for severe symptoms after discussion with oncology, with extra caution for patients on aromatase inhibitors. Ospemifene is not recommended for people with a history of breast cancer.

Counseling and sex therapy for desire, arousal, and relationship concerns; addressing depression and adjusting medications that impair sexual function.

Partner involvement and communication skills.